|
|
|
|
| LEADER |
02631nam a2200325 u 4500 |
| 001 |
EB000943135 |
| 003 |
EBX01000000000000000736725 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 020 |
|
|
|a 0309211042
|
| 020 |
|
|
|a 9780309211048
|
| 050 |
|
4 |
|a QH437
|
| 100 |
1 |
|
|a Wizemann, Theresa M.
|
| 245 |
0 |
0 |
|a Generating evidence for genomic diagnostic test development
|h Elektronische Ressource
|b workshop summary
|c Theresa Wizemann and Adam C. Berger, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies
|
| 260 |
|
|
|a Washington, D.C.
|b National Academies Press
|c c2011, 2011
|
| 300 |
|
|
|a xx, 85 p.
|b ill.
|c 23 cm
|
| 505 |
0 |
|
|a Includes bibliographical references (p. 63-66)
|
| 653 |
|
|
|a Chromosome Aberrations
|
| 653 |
|
|
|a Genetic Diseases, Inborn / diagnosis
|
| 653 |
|
|
|a Genetic Counseling
|
| 653 |
|
|
|a Genomics
|
| 700 |
1 |
|
|a Berger, Adam C.
|
| 710 |
2 |
|
|a Institute of Medicine (U.S.)
|b Roundtable on Translating Genomic-Based Research for Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 856 |
4 |
0 |
|u http://www.nap.edu/catalog.php?record_id=13133
|3 Volltext
|n Provider site
|3 Volltext
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK62412
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a "Ten years after the sequencing of the human genome, scientists have developed genetic tests that can predict a person's response to certain drugs, estimate the risk of developing Alzheimer's disease, and make other predictions based on known links between genes and diseases. However, genetic tests have yet to become a routine part of medical care, in part because there is not enough evidence to show they help improve patients' health.The Institute of Medicine (IOM) held a workshop to explore how researchers can gather better evidence more efficiently on the clinical utility of genetic tests. Generating Evidence for Genomic Diagnostic Test Development compares the evidence that is required for decisions regarding clearance, use, and reimbursement, to the evidence that is currently generated. The report also addresses innovative and efficient ways to generate high-quality evidence, as well as barriers to generating this evidence. Generating Evidence for Genomic Diagnostic Test Development contains information that will be of great value to regulators and policymakers, payers, health-care providers, researchers, funders, and evidence-based review groups."--Publisher's description
|